Washington University School of Medicine in St. Louis is radically advancing immunotherapy treatments and personalized cancer therapies. PICI researcher Robert D. Schreiber, PhD, has championed the power of immunotherapy for more than 25 years. He translates basic research principles into clinical trials and drives new therapeutic approaches. Matthew Gubin, PhD, Parker Bridge Scholar, works in Schreiber’s lab researching tumor growth and rejection to improve responses to checkpoint blockade therapies. Together with PICI, they focus on T-cells and activating responses for more patients and more cancer types. Robert D. Schreiber, PhD | Investigator Matthew Gubin, PhD | Bridge Scholar Related Research Project Tumor Neoantigen Selection Alliance (TESLA) Research Focus Tumor Antigen Discovery: Targeting Cancer Announcement, Our Impact, Research Update 5 Years of Transforming Cancer Immunotherapy Research Announcement, Our Impact, Research Update New CAR-T Approach Shows Promise for Lymphoma Patients Press Release Funding the Future of Cancer Research Cancer Research Heroes Improving Conventional Wisdom: From CAR-T Therapy to Diversity in STEM, Avery Posey Has Big Ideas Press Release Ute Dugan Joins PICI as Senior VP of Clinical Research Partner Highlight Seeking Solutions for Deadly Brain Tumors: ACGT Our Impact, Research Update Tackling Pancreatic Cancer with a Triple Threat
Cancer Research Heroes Improving Conventional Wisdom: From CAR-T Therapy to Diversity in STEM, Avery Posey Has Big Ideas